الفهرس Only 14 pages are availabe for public view
 |  | from | 149 |  |  |
| | | from | 149 | | |
Abstract
Background:Myeloid derived suppressor cells (MDSCs) inhibit adaptive immunity and support tumor progression by promoting tumor cell survival and metastasis. MDSCs may be involved in the pathogenesis of variouscancers. The purpose of this study wasto characterize the phenotype of MDSCs in a cohort ofEgyptian breast cancer patients and explore their possible associationwithtumor size, histopathology, hormonal markers and their levels in relation to neoadjuvant therapy intake. Methods:MDSC subsets were analyzedin peripheral blood samples by flow cytometry in 30 patients with malignant breast tumors, 10 patients with benign breast tumors and 10 healthy controls. Results:Total MDSCs, monocytic(M)-MDSCs and myelomono MDSCs were significantly higher in the patients with breast cancer compared to controls (p= 0.01, p= 0.001 and p<0.001, respectively), while immature MDSCs werelower in patients with malignancy compared to controls (p<0.001). No significant difference was observed between breast cancer patients and controlsregarding granulocytic(G)-MDSCs (p=0.1).We observed increased G-MDSC levels in patients with a tumorsize > 2 cm compared to patients with a tumor size < 2 cm(p=0.02) as well as patients with a positive family history of breast cancer compared to patients with negative family history of breast cancer (p=0.02). The frequency of myelomono MDSCs decreased (p=0.037) while the frequency of the granulocytic subset increased as the tumor grows.There was no difference in total MDSC levelsbetweenpatients with malignancy with/without pasthistory of breast cancer, distant metastasis, lymph nodes involvement, lymph vascular emboli, estrogen receptors, progesterone receptors, HER2/neu receptors andKi-67